- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02967068
VCRC Tissue Repository
VCRC Tissue Biorepository Collection Protocol
Study Overview
Status
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Katie Doyle
- Email: Kathryn.Logue@pennmedicine.upenn.edu
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3B6
- Recruiting
- St. Joseph's Healthcare
-
Contact:
- Sandra Messier
- Email: smessier@stjoes.ca
-
Toronto, Ontario, Canada, M5G 1X5
- Recruiting
- University of Toronto Mount Sinai Hospital
-
Contact:
- Nazrana Haq
- Email: Nazrana.Haq@sinaihealth.ca
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Completed
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02118
- Completed
- Boston University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Completed
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Katie Doyle
- Email: Kathryn.Logue@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, United States, 15261
- Completed
- University of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Completed
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
A total of 1000 patients with GCA, TAK, PAN, GPA, MPA, EGPA, cutaneous vasculitis and aortitis will potentially be enrolled into the VCRC Tissue Biorepository Collection Protocol.
The protocol will be conducted at the major vasculitis centers in the United States and Canada participating in selected VCRC studies. Biopsy specimens collected as standard of care for these diseases will be retrieved and used in research.
Biopsies are not performed as part of this protocol, rather we will request consent to collect biopsy specimens already collected under routine care.
Description
Inclusion Criteria:
- A participant will be deemed eligible for this study if the participant is/was enrolled in another one of the VCRC observational/longitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and/or one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).
Exclusion Criteria:
- Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.
- Unwilling to allow the use of their tissue for research.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identify genes that increase the risk of developing vasculitis
Time Frame: 1 year
|
Evaluating of clinical data and linked biopsy specimens to identify genes that increase the risk of developing vasculitis.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Peter A Merkel, MD, MPH, University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Autoimmune Diseases
- Immune System Diseases
- Respiratory Tract Diseases
- Hemorrhage
- Lung Diseases
- Skin Manifestations
- Hypersensitivity
- Hematologic Diseases
- Autoimmune Diseases of the Nervous System
- Skin Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Blood Coagulation Disorders
- Lung Diseases, Interstitial
- Hemostatic Disorders
- Hemorrhagic Disorders
- Aortic Diseases
- Vasculitis
- Purpura
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Granuloma
- Cerebral Small Vessel Diseases
- Vasculitis, Central Nervous System
- Immune Complex Diseases
- Systemic Vasculitis
- Arteritis
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Hemic and Lymphatic Diseases
- Aortic Arch Syndromes
- Granulomatosis with Polyangiitis
- Churg-Strauss Syndrome
- Giant Cell Arteritis
- Takayasu Arteritis
- Polyarteritis Nodosa
- IgA Vasculitis
- Microscopic Polyangiitis
- Aortitis
- Skin Diseases, Vascular
Other Study ID Numbers
- VCRC5511
- U54AR057319 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Giant Cell Arteritis
-
University of AarhusAarhus University Hospital; Glostrup University Hospital, Copenhagen; Vejle Hospital and other collaboratorsRecruitingGiant Cell Arteritis (GCA)Denmark
-
Groupe français d'étude des Maladies Inflammatoires...Not yet recruitingGiant Cell Arteritis (GCA)France
-
Groupe français d'étude des Maladies Inflammatoires...CompletedCardiovascular Diseases | Giant Cell Arteritis (GCA)France
-
Vastra Gotaland RegionRecruitingGiant Cell Arteritis (GCA)Sweden
-
University of EdinburghNot yet recruitingGiant Cell Arteritis (GCA)United Kingdom
-
National Institute of Allergy and Infectious Diseases...RecruitingGiant Cell Arteritis (GCA)United States
-
Hôpital NOVORecruitingGiant Cell Arteritis (GCA)France
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinNot yet recruiting
-
Insel Gruppe AG, University Hospital BernNot yet recruitingGiant Cell Arteritis (GCA)Switzerland
-
AbbVieCompletedGiant Cell Arteritis (GCA)United States, Australia, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Spain, Sweden, Switzerland, United Kingdom, Israel, Austria, Denmark, Russia